NanoBio Closes $11M Series C Financing

NanoBio Corporation, an Ann Arbor, Michigan-based biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal & intramuscular vaccines derived from its patented NanoStatâ„¢ technology platform, has closed an $11m Series C financing.

Backers include existing investors.

Led by David Peralta, CEO, NanoBio is developing treatments for herpes labialis, onychomycosis, vaginitis, cystic fibrosis and a broad platform of nanoemulsion-based vaccines.

The company intends to use the funding to advance its development programs for herpes labialis (cold sores), cystic fibrosis and nanoemulsion-based vaccines for respiratory syncytial virus (RSV) and genital herpes (HSV2).



Join the discussion